Zimmer Biomet to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Zimmer Biomet (NYSE: ZBH) announced that members of its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 a.m. PT (11:15 a.m. ET).
A live webcast will be available on Zimmer Biomet's Investor Relations website and will be archived for replay after the conference.
Positive
- None.
Negative
- None.
News Market Reaction – ZBH
In the Dec 22 session, ZBH gained 0.75%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Dividend declaration | Positive | +0.7% | Announced a $0.24 per share quarterly cash dividend for Q4 2025. |
| Dec 16 | Digital partnership | Positive | -1.6% | Exclusive collaboration with OneStep to add mobility analytics to mymobility. |
| Nov 14 | FDA clearance | Positive | -0.7% | Received U.S. FDA 510(k) clearance for enhanced ROSA Knee with OptimiZe. |
| Nov 07 | Conference appearance | Neutral | -0.0% | Announced participation and webcast for Jefferies Global Healthcare Conference. |
| Nov 05 | Earnings release | Neutral | -15.2% | Reported Q3 2025 results with higher sales and acquisitions; shares fell sharply. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive operational news (collaborations, FDA clearance) has not consistently led to positive next-day moves, and a major earnings release saw a double-digit decline, suggesting sensitivity to financial details and guidance.
This announcement follows a series of varied catalysts. On Nov 5, 2025, ZBH reported Q3 net sales of $2.001B and adjusted diluted EPS of $1.90, but shares fell 15.15%. Subsequent news included an FDA 510(k) clearance for the enhanced ROSA Knee system and a digital mobility collaboration with OneStep, both followed by modest negative reactions. A Jefferies conference appearance in early November had little price impact, while a $0.24 quarterly dividend declaration on Dec 17, 2025 saw a mild positive move.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.
Contacts: Media Troy Kirkpatrick 614-284-1926 troy.kirkpatrick@zimmerbiomet.com
781-779-5561 | Investors David DeMartino 646-531-6115 david.demartino@zimmerbiomet.com
908-591-6955 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302647147.html
SOURCE Zimmer Biomet Holdings, Inc.